Through its unique ability to mimic nature, PepMeticsTM Technology unlocks undruggable targets.
PRISM’s projects for CBP/β-Catenin inhibition and eIF4E/eIF4G1 inhibition were both previously thought to be undruggable.
Platform Collaboration Pipeline:
PRISM collaborates with pharmaceutical and biotech companies, challenging novel targets and unmet medical needs.
FEP: Cancer (Seeking Collaboration)
FEP633, A Novel Binding Inhibitor of eIF4E/eIF4G1
- 4E-BP1 is a repressor protein of eIF4E. Along with phosphorylation of 4E-BP1 via mTORC1, eIF4E is unbonded from 4E-BP1 and binds to eIF4G1. This is a critical path to initiate CAP dependent translation
- It has been reported advanced tumors often show higher expressions of phosphorylated 4E-BP1
- FEP600 is a mimetic compound to 4E-BP1 and suppresses eIF4E binding to eIF4G1
- FEP633 is a prodrug of FEP600 at the final stage of lead optimization
With PDX models derived from urothelial carcinoma, FEP600 was shown to be more efficacious than Cisplatin, the current Standard of Care.